What We have Learned about Pain from Rodent Models of Arthritis?

被引:0
作者
Inglis, Julia J. [1 ,2 ]
Schutze, Mark U. [3 ]
McNamee, Kay E. [4 ]
机构
[1] Murdoch Univ, Sch Vet & Biomed Sci, Perth, WA, Australia
[2] Univ Western Australia, Sch Med & Pharmacol, Nedlands, WA, Australia
[3] Sir Charles Gairdner Hosp, Dept Pain Management, Perth, WA, Australia
[4] Imperial Coll London, London W6 8LH, England
关键词
Pain mechanisms; animal models; rodent; osteoarthritis; rheumatoid arthritis; analgesics;
D O I
10.2174/157339710791792748
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Rheumatoid arthritis (RA) and Osteoarthritis (OA) are both common diseases of the joints. RA is distinguished by inflammation and synovitis leading to joint destruction, whereas OA is typified by degenerative and mostly noninflammatory disease. Although differing in their pathology, both forms can elicit chronic disabling pain in patients. Relief from this pain is an unmet need for many patients, and this has lead to a drive to understand the pain mechanisms occurring in each disease in order to develop new analgesics. This necessitates the use of pre-clinical models. Here we discuss the methods and limitations of animal pain assessment, rodent models of RA and OA, and how these models have been used to investigate the genesis of pain. Specifically, we focus on processes studied in both RA and OA models, and how the mediators involved in the development of pain may differ between these two arthritic states and during acute and chronic pain. From this we have learnt that the key mediators of RA pain include inflammatory cells, inflammatory cytokines, astrocytes, substance P, and CGRP. Endogenous analgesic mediators in RA include beta-endorphin, mu-opioid receptor, and various anti-inflammatory cytokines. Less is known of the mediators of OA pain, but important factors include CGRP, TRPV1, NGF, VIP and the mu-opioid receptor. Interestingly, several factors have been found not to play a role in OA pain, including glial cells, neutrophils and TNF. It must be noted that the vast majority of candidate drugs from animal research never reach the human clinic, in part due to false positives from animal models. This may be due to flaws in the models themselves, the methods used to assess pain, the physical properties of the candidate drug, or an inherent difference between animal and human pain pathways. By developing more clinically relevant models, novel diseasespecific analgesics are being developed with the hope of improving the quality of life for sufferers of arthritis pain.
引用
收藏
页码:194 / 207
页数:14
相关论文
共 50 条
  • [31] What we learn from arthritis models to benefit arthritis patients
    van den Berg, WB
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2000, 14 (04): : 599 - 616
  • [32] Imaging the painful osteoarthritic knee joint: what have we learned?
    Wenham, Claire Y. J.
    Conaghan, Philip G.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2009, 5 (03): : 149 - 158
  • [33] Imaging in osteoarthritis: what have we learned and where are we going?
    Hayashi, D.
    Guermazi, A.
    Crema, M. D.
    Roemer, F. W.
    MINERVA MEDICA, 2011, 102 (01) : 15 - 32
  • [34] What have we learned from six years of GWAS in autoimmune diseases, and what is next?
    Hu, Xinli
    Daly, Mark
    CURRENT OPINION IN IMMUNOLOGY, 2012, 24 (05) : 571 - 575
  • [35] What have we learned from long-term studies in juvenile idiopathic arthritis? - Prediction, classification, transition.
    Rygg, Marite
    Ramos, Filipa Oliveira
    Nordal, Ellen Berit
    PEDIATRIC RHEUMATOLOGY, 2025, 23 (01)
  • [36] New knowledge on the pathogenesis of chronic inflammatory bowel disease:: what have we learned from colitis animal models
    Seibold, F
    Egger, B
    Göke, B
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 2000, 130 (20) : 749 - 755
  • [37] Neurophysiology of the Developing Cerebral Cortex: What We Have Learned and What We Need to Know
    Luhmann, Heiko J.
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2022, 15
  • [38] Posttraumatic osteoarthritis: what have we learned to advance osteoarthritis?
    Watt, Fiona E.
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (01) : 74 - 83
  • [39] CCR1 Antagonists: What Have We Learned From Clinical Trials
    Gladue, Ronald P.
    Brown, Matthew F.
    Zwillich, Samuel H.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (13) : 1268 - 1277
  • [40] Malignancy in systemic lupus erythematosus: what have we learned?
    Bernatsky, Sasha
    Ramsey-Goldman, Rosalind
    Clarke, Ann E.
    BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2009, 23 (04): : 539 - 547